Your browser doesn't support javascript.
loading
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
Shadman, Mazyar; Ahn, Kwang W; Kaur, Manmeet; Lekakis, Lazaros; Beitinjaneh, Amer; Iqbal, Madiha; Ahmed, Nausheen; Hill, Brian; Hossain, Nasheed M; Riedell, Peter; Gopal, Ajay K; Grover, Natalie; Frigault, Matthew; Brammer, Jonathan; Ghosh, Nilanjan; Merryman, Reid; Lazaryan, Aleksandr; Ram, Ron; Hertzberg, Mark; Savani, Bipin; Awan, Farrukh; Khimani, Farhad; Ahmed, Sairah; Kenkre, Vaishalee P; Ulrickson, Matthew; Shah, Nirav; Kharfan-Dabaja, Mohamed A; Herrera, Alex; Sauter, Craig; Hamadani, Mehdi.
  • Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Ahn KW; Division of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA.
  • Kaur M; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Lekakis L; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Beitinjaneh A; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Iqbal M; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Ahmed N; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
  • Hill B; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
  • Hossain NM; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
  • Riedell P; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, USA.
  • Gopal AK; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Grover N; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Frigault M; Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA.
  • Brammer J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Ghosh N; Division of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA.
  • Merryman R; Lineberger Comprehensive Cancer Center, Department of Medicine, Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Lazaryan A; Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA, USA.
  • Ram R; Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Hertzberg M; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Savani B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Awan F; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Khimani F; Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Ahmed S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Kenkre VP; Prince of Wales Hospital, Sydney, NSW, Australia.
  • Ulrickson M; Long Term Transplant Clinic, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Shah N; Division of Hematology and Oncology, UT Southwestern, Dallas, TX, USA.
  • Kharfan-Dabaja MA; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Herrera A; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sauter C; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hamadani M; Division of Hematology, Oncology, Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI, USA.
Blood Cancer J ; 14(1): 108, 2024 Jul 08.
Article en En | MEDLINE | ID: mdl-38977682
ABSTRACT
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015-2021) vs. CAR-T (2018-2021) using the Center for International Blood & Marrow Transplant Research registry. Median follow-up was 49.7 months for the auto-HCT and 24.7 months for the CAR-T cohort. Patients ages 18 and 75 with a diagnosis of DLBCL were included if they received auto-HCT (n = 281) or commercial CAR-T (n = 79) while in a CR. Patients undergoing auto-HCT with only one prior therapy line and CAR-T patients with a previous history of auto-HCT treatment were excluded. Endpoints included Progression-free survival (PFS), relapse rate, non-relapse mortality (NRM) and overall survival (OS). In univariate analysis, treatment with auto-HCT was associated with a higher rate of 2-year PFS (66.2% vs. 47.8%; p < 0.001), a lower 2-year cumulative incidence of relapse (27.8% vs. 48% ; p < 0.001), and a superior 2-year OS (78.9% vs. 65.6%; p = 0.037). In patients with early (within 12 months) treatment failure, auto-HCT was associated with a superior 2-year PFS (70.9% vs. 48.3% ; p < 0.001), lower 2-year cumulative incidence of relapse (22.8% vs. 45.9% ; p < 0.001) and trend for higher 2-year OS (82.4% vs. 66.1% ; p = 0.076). In the multivariable analysis, treatment with auto-HCT was associated with a superior PFS (hazard ratio 1.83; p = 0.0011) and lower incidence of relapse (hazard ratio 2.18; p < 0.0001) compared to CAR-T. In patients with relapsed LBCL who achieve a CR, treatment with auto-HCT is associated with improved clinical outcomes compared to CAR-T. These data support the consideration of auto-HCT in select patients with LBCL achieving a CR in the relapsed setting.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante Autólogo / Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante Autólogo / Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article